Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$12.70M+107.85%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stephen Gunstream
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 158
- Beta
- 0.73
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 6.33
Financials
Revenue
$12.70M+107.9%Net Income
$-3.49M-468.1%EBITDA
$-3.20M-318.2%Free Cash Flow
$-1.40MEPS (diluted)
$-0.06-889.5%Shares Outstanding (diluted)
53.69M+1376.4%Operating Expenses
$7.75MCash & Debt
$16.56MReturn of Capital
$0.00Revenue by Segment (annual)
$40.52MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $40.52M | $-17.26M | $-0.32 |
| 2024 | $37.74M | $-26.75M | $-0.57 |
| 2023 | $36.68M | $-36.78M | $-1.16 |
| 2022 | $41.42M | $-47.47M | $-1.69 |
| 2021 | $36.89M | $-9.80M | $-0.35 |
| 2020 | $31.30M | $3.57M | $0.16 |
| 2019 | $20.09M | $-1.30M | $-0.36 |
Valuation
TKNOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (16)
- Newszacks.com·4d ago·Positive
Wall Street Analysts Think Alpha Teknova (TKNO) Could Surge 26.41%: Read This Before Placing a Bet The mean of analysts' price targets for Alpha Teknova (TKNO) points to a 26.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
Alpha Teknova Q3 Earnings Call Highlights Alpha Teknova NASDAQ: TKNO raised its 2026 revenue guidance after reporting a second consecutive quarter of record revenue, as demand for custom products from biopharma, life science tools and diagnostics customers helped drive 22% year-over-year growth.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Alpha Teknova, Inc. (TKNO) Q3 2026 Earnings Call Transcript Alpha Teknova, Inc. (TKNO) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·18d ago·Negative
Alpha Teknova (TKNO) Reports Q3 Loss, Tops Revenue Estimates Alpha Teknova (TKNO) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago.
View source ↗ - Newszacks.com·30d ago·Neutral
Alpha Teknova (TKNO) Stock Jumps 5.1%: Will It Continue to Soar? Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
…nova to Report Third Quarter 2026 Financial Results on November 4, 2026 HOLLISTER, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2026, on Wednesday, November 4, 2026, following the close of market…
View source ↗ - Newsglobenewswire.com·33d ago·Negative
…eknova Announces Pricing of $40 Million Public Offering of Common Stock HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the…
View source ↗ - Newsglobenewswire.com·33d ago·Negative
Teknova Announces Proposed Public Offering of Common Stock HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has commenced an underwritten public offering of its common stock. Teknova also intends to grant the underwriters a 30-day option to purchase up to an additional fif…
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Teknova Announces Preliminary Third Quarter Financial Results HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced in conjunction with its filing of a preliminary prospectus supplement, preliminary unaudited financial results for the three months ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·51d ago·Negative
Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System Teknova and Pluristyx announce a Type II FDA Drug Master File for the PluriFreeze™ cryopreservation system, now available to developers for cross-reference
View source ↗ - Newszacks.com·52d ago·Positive
All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsdefenseworld.net·58d ago·Negative
88,412 Alpha Teknova, Inc. $TKNO Shares Sold by Squarepoint Ops LLC Squarepoint Ops LLC reduced its stake in shares of Alpha Teknova, Inc. (NASDAQ: TKNO) by 71.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,948 shares of the company's stock after selling 88,412 shares during the quarter. Squarepoint
View source ↗ - Newszacks.com·61d ago·Neutral
Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last? Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - Newsglobenewswire.com·67d ago·Neutral
Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling Teknova's Fill-Tek™ Dispensing System fills single-use bag orders across multiple sizes and quantities as a single lot, with no added turnaround time.
View source ↗ - Newsmarketbeat.com·95d ago·Neutral
Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference Alpha Teknova NASDAQ: TKNO Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve.
View source ↗ - Newszacks.com·95d ago·Positive
Alpha Teknova (TKNO) is a Great Momentum Stock: Should You Buy? Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.07 per share
Typical surprise +16.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.06 vs $-0.07beat
- Wed, Aug 5$-0.06 vs $-0.08beat
- Wed, May 6$-0.08 vs $-0.09beat
- Thu, Feb 26$-0.09 vs $-0.09beat
- Thu, Nov 6$-0.08 vs $-0.09beat
- Thu, Aug 7$-0.07 vs $-0.10beat
Estimates and results for TKNO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TKNO officers and directors.
- Bought
- $32.7m
- Sold
- $101k
34 trades
4 trades
- Lowell Matthewbought
- Gunstream Stephenbought
- Demski Martha Jsold
- Telegraph Hill Partners Iv, L.p.bought
- Telegraph Hill Partners Iv, L.p.bought
- Lowell Matthewbought
- Gunstream Stephenbought
- Gelhaus Kenbought
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (34d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (29d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (33d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (21d later)Sell$15,001 - $50,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (28d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (40d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (29d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (25d later)Sell$15,001 - $50,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (22d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (29d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (26d later)Sell$15,001 - $50,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (43d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (43d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (29d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (27d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (35d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (41d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (33d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (21d later)Sell$1,001 - $15,000
- Richard Blumenthalsenate · CT · disclosed Sep 1, 2026 (43d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
